Dr. Scott Rocklage is a Managing Partner of 5AM Ventures. He acquired the position in 2004, a year after he joined the firm as a Venture Partner. He has more than three decades of management experience and leadership in healthcare services. Read more: Scott Rocklage | Rennovia
He played a pivotal role in the development of three drugs, Omniscan, Cubicin, and Teslascan, which were approved by Food and Drug Administration. Dr. Rocklage has also managed to enter several drug candidates into medical trials. Dr. Scott Rocklage has invented and helped invent at least 30 U.S. patents. He has over 100 peer-reviewed publications.
Scott Rocklage has served as President and CEO of Nycomed Salutar as well as Chairman and Chief Executive Officer of Cubist Pharmaceuticals. He has also held different Research and Development positions at Catalytica and Salutar.
He was once the Board Chairman of Novira and Relypsa (NASDAQ: RLYP). He was also the Executive Chairman of Semprus (acquired by Teleflex), Miikana (acquired by EntreMed), and Ilypsa (acquired by Amgen). At the moment, he is the Board Chairman of Kinestral, Rennovia, and Cidara (NASDAQ: CDTX). Dr. Rocklage also features in the Boards of Pulmatrix (NASDAQ: PULM) and Epirus (NASDAQ: EPRS).
Dr. Scott Rocklage achieved his B.S. in Chemistry at the University of California, Berkely. At MIT (Massachusetts Institute of Technology), he received his PhD in Chemistry after extensive research in the lab of Richard R. Schrock (Nobel Prize in Chemistry in 2005).
Scott Rocklage spends most of his time researching on new disciplines of life science. He also spends time in board meetings as well as working with 5AM Ventures’ portfolio management team. He likes to help physicians, scientists, and business executives to develop their ideas into remedies for unsolved medical conditions. Learn more about Scott Rocklage: https://thebrotalk.com/bro-bio/bro-bio-enigmatic-mysterious-life-dr-scott-rocklage/
As an entrepreneur, Scott Rocklage is very keen on making priorities, time management, and scheduling. He focuses on team selection at the formation of a new company to ensure that he hires the right people.
One thing that excites Dr. Rocklage is the ability to target particular genotypes or mutations to treat cancer. This advancement in medical technology enables him to save lives, and future improvements will only promote the quality of life.